Cara Therapeutics Inc (CARA) CEO Derek T. Chalmers Sells 20,000 Shares

Cara Therapeutics Inc (NASDAQ:CARA) CEO Derek T. Chalmers sold 20,000 shares of Cara Therapeutics stock in a transaction that occurred on Tuesday, July 10th. The stock was sold at an average price of $20.64, for a total value of $412,800.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shares of Cara Therapeutics traded up $0.31, hitting $21.83, during trading on Thursday, according to MarketBeat.com. 810,518 shares of the company traded hands, compared to its average volume of 1,130,533. Cara Therapeutics Inc has a 1 year low of $11.11 and a 1 year high of $22.29. The stock has a market capitalization of $677.54 million, a PE ratio of -11.74 and a beta of 3.01.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.04). sell-side analysts forecast that Cara Therapeutics Inc will post -2.17 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in CARA. BlackRock Inc. grew its stake in shares of Cara Therapeutics by 25.6% during the 4th quarter. BlackRock Inc. now owns 2,207,407 shares of the biopharmaceutical company’s stock valued at $27,018,000 after buying an additional 449,334 shares during the period. Nexthera Capital LP purchased a new stake in Cara Therapeutics during the 1st quarter worth $4,346,000. ETF Managers Group LLC boosted its position in Cara Therapeutics by 165.8% during the 1st quarter. ETF Managers Group LLC now owns 337,486 shares of the biopharmaceutical company’s stock worth $3,992,000 after purchasing an additional 210,534 shares during the period. UBS Group AG boosted its position in Cara Therapeutics by 359.1% during the 1st quarter. UBS Group AG now owns 178,260 shares of the biopharmaceutical company’s stock worth $2,207,000 after purchasing an additional 139,436 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in Cara Therapeutics by 732.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 78,811 shares of the biopharmaceutical company’s stock worth $964,000 after purchasing an additional 91,275 shares during the period. 54.42% of the stock is owned by institutional investors.

Several research analysts recently issued reports on the company. ValuEngine upgraded Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. BidaskClub raised shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 28th. Canaccord Genuity reaffirmed a “buy” rating and issued a $22.00 target price (up from $21.00) on shares of Cara Therapeutics in a research note on Thursday, June 28th. HC Wainwright lifted their target price on shares of Cara Therapeutics from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday, June 28th. Finally, Needham & Company LLC lifted their target price on shares of Cara Therapeutics from $23.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, June 27th. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Cara Therapeutics has a consensus rating of “Buy” and an average target price of $24.75.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply